Research Topic

Therapeutics Targeting Intracellular Bacteria

About this Research Topic

Intracellular bacteria are among the deadliest pathogens, and novel therapeutics are urgently needed to combat the diseases caused by them. Intracellular bacteria can be characterized as obligate and facultative, obligate intracellular bacteria needs a host cell to develop within it, and the facultative intracellular bacteria can replicate in and outside of the host cell. Certain species of bacteria can localize inside the host cells, followed by multiplication and modulation of the host cell biology. The classic examples of intracellular bacteria are Mycobacterium tuberculosis, Salmonella enterica, Chlamydia trachomatis, Neisseria gonorrhea, Francisella tularensis, Yersinia pestis, and Listeria monocytogenes.

The bacterial intracellular survival system allows the bacteria to survive inside the host and against the host's defense. Additionally, evidence suggests that some classical extracellular bacteria, such as Staphyloccus aureus, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii can also invade and localize inside host cells which protect from both the antibacterials and the host immune system.

Lastly, antibacterial agents for clinical use are deficient in clearing intracellular bacterial load, due to limiting factors, such as poor intracellular penetration of most common clinical antibiotics resulting in chronic and unresolved infections.

This topic would be of broad scientific interest, with particular focus on:
· Novel antibacterial agents targeting intracellular bacteria
· Clinical antibiotic molecules with nanoparticles formulation to enhance an anti-intracellular bacterial activity.
· Carriers used for targeted-intracellular delivery of clinical antibiotics or novel compounds to eradicate intracellular bacteria

We welcome the following manuscript types in this Research Topic: a) Reviews, b) Opinions c) Methods, and d) Original Research articles about "therapeutics to eradicate intracellular bacteria".


Keywords: Intracellular bacteria, therapeutics, intracellular drug delivery, clinical antibiotics, novel compounds, antibacterial, Mycobacterium tuberculosis, Salmonella enterica, Chlamydia trachomatis, Neisseria gonorrhea, Francisella tularensis, Yersinia pestis, and Listeria monocytogenes


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Intracellular bacteria are among the deadliest pathogens, and novel therapeutics are urgently needed to combat the diseases caused by them. Intracellular bacteria can be characterized as obligate and facultative, obligate intracellular bacteria needs a host cell to develop within it, and the facultative intracellular bacteria can replicate in and outside of the host cell. Certain species of bacteria can localize inside the host cells, followed by multiplication and modulation of the host cell biology. The classic examples of intracellular bacteria are Mycobacterium tuberculosis, Salmonella enterica, Chlamydia trachomatis, Neisseria gonorrhea, Francisella tularensis, Yersinia pestis, and Listeria monocytogenes.

The bacterial intracellular survival system allows the bacteria to survive inside the host and against the host's defense. Additionally, evidence suggests that some classical extracellular bacteria, such as Staphyloccus aureus, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii can also invade and localize inside host cells which protect from both the antibacterials and the host immune system.

Lastly, antibacterial agents for clinical use are deficient in clearing intracellular bacterial load, due to limiting factors, such as poor intracellular penetration of most common clinical antibiotics resulting in chronic and unresolved infections.

This topic would be of broad scientific interest, with particular focus on:
· Novel antibacterial agents targeting intracellular bacteria
· Clinical antibiotic molecules with nanoparticles formulation to enhance an anti-intracellular bacterial activity.
· Carriers used for targeted-intracellular delivery of clinical antibiotics or novel compounds to eradicate intracellular bacteria

We welcome the following manuscript types in this Research Topic: a) Reviews, b) Opinions c) Methods, and d) Original Research articles about "therapeutics to eradicate intracellular bacteria".


Keywords: Intracellular bacteria, therapeutics, intracellular drug delivery, clinical antibiotics, novel compounds, antibacterial, Mycobacterium tuberculosis, Salmonella enterica, Chlamydia trachomatis, Neisseria gonorrhea, Francisella tularensis, Yersinia pestis, and Listeria monocytogenes


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

11 November 2020 Abstract
08 March 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

11 November 2020 Abstract
08 March 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..